-
Mashup Score: 2Perioperative Nivolumab in Resectable Lung Cancer | NEJM - 1 hour(s) ago
Standard treatment with neoadjuvant nivolumab plus chemotherapy significantly improves outcomes in patients with resectable non–small-cell lung cancer (NSCLC). Perioperative treatment (i.e., neoadj…
Source: www.nejm.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 40First-line osimertinib for lung cancer with uncommon EGFR exon 19 mutations and EGFR compound mutations - 8 hour(s) ago
Up to 20% of EGFR-mutated non-small cell lung cancer (NSCLC) cases harbor uncommon EGFR mutations, including atypical exon 19 and compound mutations. Relatively little is known about the efficacy of osimertinib in these cases.
Source: www.jtocrr.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 141Perioperative Nivolumab in Resectable Lung Cancer | NEJM - 18 hour(s) ago
Standard treatment with neoadjuvant nivolumab plus chemotherapy significantly improves outcomes in patients with resectable non–small-cell lung cancer (NSCLC). Perioperative treatment (i.e., neoadj…
Source: www.nejm.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 141Perioperative Nivolumab in Resectable Lung Cancer | NEJM - 20 hour(s) ago
Standard treatment with neoadjuvant nivolumab plus chemotherapy significantly improves outcomes in patients with resectable non–small-cell lung cancer (NSCLC). Perioperative treatment (i.e., neoadj…
Source: www.nejm.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 141Perioperative Nivolumab in Resectable Lung Cancer | NEJM - 20 hour(s) ago
Standard treatment with neoadjuvant nivolumab plus chemotherapy significantly improves outcomes in patients with resectable non–small-cell lung cancer (NSCLC). Perioperative treatment (i.e., neoadj…
Source: www.nejm.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 134
Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) and immune checkpoint inhibitors (ICIs) such as programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) inhibitors have dramatically improved the prognosis of patients with non-small cell lung cancer (NSCLC). However, these drugs can also cause pulmonary complications. The prevalence of interstitial pneumonitis (IP) following EGFR-TKI administration is reportedly 0.3–4.3%, and the mortality is 20–50%.1 Treatment with ICIs can lead to immune-related adverse events in various organs; the proportion of ICI-associated pneumonitis reportedly ranges from 3.5–19%.
Source: www.clinical-lung-cancer.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 45
Surgical resection of pulmonary adenocarcinoma is considered to be curative but progression-free survival (PFS) has remained highly variable. Antitumor immune response may be important, however, the prognostic significance of tumor-infiltrating natural killer (NK) and regulatory T (Treg) lymphocytes is uncertain. Resected pulmonary adenocarcinoma tissues (n = 115) were studied by immunohistochemical detection of NKp46 and FoxP3 positivity to identify NK and Treg cells, respectively. Association of cell densities with clinicopathological features and progression-free survival (PFS) as well as overall survival (OS) were analyzed with a follow-up time of 60 months.
Source: www.lungcancerjournal.infoCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 49Best Practice for RET NSCLC | IASLC - 4 day(s) ago
Host Dr. Stephen Liu moderates a discussion on RET as a therapeutic target in this episode of Lung Cancer Considered. RET fusions are a known actionable alterat …
Source: www.iaslc.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 38Capmatinib plus nivolumab in pretreated patients with EGFR wild-type advanced non–small cell lung cancer - 5 day(s) ago
Mesenchymal-epithelial transition factor (MET) pathway dysregulation may occur through various mechanisms including MET overexpression, MET gene amplification, or MET exon 14 skipping (METex14) mutations [1–3]. Dysregulated MET is an established oncogenic driver in non–small cell lung cancer (NSCLC) [1,4–7]. In addition to its role in tumor cells, MET signaling may also modulate immune function leading to suppression of anticancer immune responses and MET overexpression or activation could play a role in tumor immune evasion [8–13].
Source: www.lungcancerjournal.infoCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 67Decoding Biomarker Testing and Targeted Therapy in NSCLC: The Complete Guide for 2024 - 6 day(s) ago
See the latest #TargetedTherapy #NSCLC live event from @PeerView, @StephenVLiu, @benlevylungdoc, @JessicaJLinMD, @peters_solange #ASCO24 #MedEd
Source: lrn.peerview.comCategories: General Medicine News, Hem/OncsTweet-
Saturday, June 1, 7pm CDT at #ASCO24 - join Drs. @benlevylungdoc @JessicaJLinMD @peters_solange and me for a free comprehensive #CME symposium on targeted therapy in NSCLC. We cover it all in 90min! Register now, live/virtual: https://t.co/qXn1MkYSgm [https://t.co/1YOhTYaQSq] https://t.co/pLU8XEql76
-
Now @NEJM from Dr. Tina Cascone et al - phase 3 CheckMate 77T results: addition of neoadjuvant plus adjuvant nivolumab to neoadjuvant chemo in pts with resectable NSCLC improves pCR (25.3% to 4.7%) and EFS (HR 0.58) with no new safety signals. https://t.co/e4kwppw25t